XKDCT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XKDCT-023’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XKDCT-023 overview

XKDCT023 is under development for the treatment of CD19 positive recurrent or refractory diffuse large B cell lymphoma, solid tumor, lung cancer, ovarian cancer, esophageal cancer, stomach cancer, pancreatic cancer, endometrial cancer, cervical cancer, breast thyroid cancer, colorectal cancer, prostate cancer. The therapeutic candidate comprises T-cells genetically engineered to express chimeric antigen receptor (CAR) targeting cells expressing CD19.

Shenzhen Xiankangda Life Sciences overview

Shenzhen Xiankangda Life Sciences (Xiankangda Life Sciences) operate in healthcare sector. Xiankangda Life Sciences is headquartered in Shenzhen, Guangdong, China.

For a complete picture of XKDCT-023’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.